Nasdaq · ADR · Pharmaceutical Preparations
18 entities across 18 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-03-02 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Amarin Pharmaceuticals Ireland Limited | Ireland | |
| Amarin Pharma, Inc. | United States | |
| Ester Neurosciences Limited | Israel | |
| Amarin Switzerland GmbH | Switzerland | |
| Amarin Germany GmbH | Germany | |
| Amarin France SAS | France | |
| Amarin UK Limited | United Kingdom | |
| Amarin Italy S.r.l | Italy | |
| Amarin Switzerland GmbH Sucursal Espana | Spain | |
| Amarin Switzerland GmbH Austrian branch | Austria | |
| Amarin Belgium, branch of Amarin Switzerland GmbH | Belgium | |
| Amarin Denmark, filial af Amarin Switzerland GmbH | Denmark | |
| Amarin Switzerland GmbH, Suomen sivuliike | Finland | |
| Amarin Switzerland GmbH Greek branch | Greece | |
| Amarin Switzerland GmbH Dutch branch | Netherlands | |
| Amarin Switzerland GmbH Norwegian branch | Norway | |
| Amarin Switzerland GmbH, Sucursal em Portugal | Portugal | |
| Amarin Switzerland GmbH Sweden filial | Sweden |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $614.1M | −$18.0M | −$22.0M | 78.6% | 381,759,000 |
| FY2021 | $583.2M | $7.7M | — | 79.2% | 402,480,000 |
| FY2022 | $369.2M | −$105.8M | — | 65.7% | 401,155,000 |
| FY2023 | $306.9M | −$59.1M | — | 53.9% | 407,655,000 |
| FY2024 | $228.6M | −$82.2M | — | 35.6% | 410,937,000 |
| FY2025 | $213.6M | −$38.8M | — | 56.6% | 414,984,000 |
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
AMARIN CORP PLC\UK files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
